July 2, 2014

Health care providers wrote 259 million prescriptions for opioid painkillers in 2012 — many more in some states than in others — according to a Vital Signs report released Tuesday by the Centers for Disease Control and Prevention that highlights the danger of overdose.

June 30, 2014

Actavis on Monday confirmed that it has filed an abbreviated new drug application with the Food and Drug Administration to market buprenorphine hydrochloride and naloxone hydrochloride dihydrate sublingual tablets.

June 26, 2014

The Acetaminophen Awareness Coalition on Thursday released “Acetaminophen: How It’s Used, Preventing Overdose and What We Can Do to Promote Safe Use,” a report and educational resource to drive safe and appropriate use of one of the United States’ most common drug ingredients.

June 20, 2014

In an effort to address opioid drug abuse, governors of five New England states convened for a summit on Monday, the National Association of Boards of Pharmacy stated.

June 17, 2014

Lannett Co. received approval from the Food and Drug Administration for codeine sulfate tablets USP, a schedule II controlled substance, in 15 mg, 30 mg and 60 mg dosage strengths.

June 17, 2014

As the heroin and opioid epidemic spreads through communities across the United States, Sens. Carl Levin, D-Mich., and Orrin Hatch, R-Utah, will hold a forum on Wednesday to discuss opioid addiction, focusing on the use of buprenorphine to help combat opioid abuse and the obstacles that have prevented even more patients from getting buprenorphine treatment. 


June 9, 2014

BioDelivery Sciences International on Monday announced that the Food and Drug Administration approved its new drug application for Bunavail (buprenorphine and naloxone) buccal film (CIII).

May 29, 2014

Depomed on Wednesday announced that the Food and Drug Administration has accepted for filing a new drug application from Mallinckrodt for MNK-155.

May 29, 2014

Louisiana became the sixth state to prohibit minors from purchasing over-the-counter cough medicines containing dextromethorphan as Gov. Bobby Jindal signed HB 514 into law.

May 14, 2014

Actavis on Tuesday announced that it has received final approval from the Food and Drug Administration on its abbreviated new drug application for a generic version of Mallinckrodt's Exalgo (hydromorphone hydrochloride extended-release tablets 8 mg, 12 mg and 16 mg).

May 2, 2014

The Consumer Healthcare Products Association on Wednesday commended Arizona Governor Jan Brewer for signing H.B. 2086 in to law.

May 1, 2014

Purdue Pharma on Wednesday announced that it filed a new drug application with the Food and Drug Administration to market a hydrocodone bitartrate tablet, which is formulated to incorporate abuse-deterrent technology.

April 24, 2014

A cough syrup produced by Actavis will no longer be available due to the negative light cast on the product stemming from abuse by musicians like Justin Bieber and Soulja Boy, according to a report from the Huffington Post.

April 3, 2014

The Food and Drug Administration on Thursday approved a prescription treatment that can be used by family members or caregivers to treat a person known or suspected to have had an opioid overdose.

March 31, 2014

In an effort to curb abuse of over-the-counter cold and cough medications by minors, Washington Gov. Jay Inslee on Friday signed legislation — House Bill 2163 — that places an age restriction on the purchase of dextromethorphan.

March 28, 2014

DSN recently launched a new microsite, DrugStoreNews.com/Pain-Management, to bring attention to a tragic side of the prescription drug abuse story — one that's not often told. The millions of Americans who live in chronic pain who already find it difficult to access the medications they need may soon find it even more difficult — because proposed changes in regulatory policy are expected to place additional hurdles on their treatment pathway.

March 28, 2014

Pharmacists in New Mexico have become the first in the United States certified to prescribe Narcan (naloxone), which prevents or reverses the effects of opioids including respiratory depression, sedation and hypotension, according to a report published Wednesday by The New Mexican.

March 25, 2014

The Drug Store News Group, the leading provider of news, information and clinical education for the retail pharmacy industry, has launched the new microsite, Drugstorenews.com/pain-management, to help bring attention to another tragic side of the prescription drug abuse story — the millions of Americans who live in chronic pain that may be unable to access the medications they need thanks to proposed changes in regulatory policy.

March 20, 2014

Purdue Pharma recently announced that a Phase 3 study of an investigational extended‐release formulation of hydrocodone bitartrate met its primary efficacy endpoint by showing that patients with chronic low back pain treated with the once‐daily analgesic agent experienced statistically significant reduction in pain compared with placebo.

March 18, 2014

Mallinckrodt Plc last week announced that the Food and Drug Administration approved Xartemis XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII), for the management of acute pain severe enough that it requires opioid treatment.

March 14, 2014

In observance of National Poison Prevention Week, which is March 16 to 22, the National Safety Council has released a list of facts many people do not — but need to — know about prescription painkiller use.

March 5, 2014

Most people who abuse prescription opioid drugs get them for free from a friend or relative — but those at highest risk of overdose are as likely to get them from a doctor’s prescription, Centers for Disease Control researchers reported Monday in a research letter, “Sources of Prescription Opioid Pain Relievers by Frequency of Past-Year Nonmedical Use: United States, 2008-2011,” in the Journal of the American Medical Association Internal Medicine.

March 5, 2014

In what could turn into a significant change of how retail pharmacy supplies hydrocodone combination products, the Drug Enforcement Administration last week published in the Federal Register a Notice of Proposed Rulemaking to move HCPs from Schedule III to Schedule II, as recommended by the assistant secretary for health of the Department of Health and Human Services and as supported by the DEA’s evaluation of relevant data.

February 24, 2014

Concurrent opioid prescribing by multiple providers is common in Medicare patients and is associated with higher rates of hospital admission related to opioid use, according to a study published last week in BMJ.